Clinical Trial Update: Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study [Phase 2]

View source ↗

Summary

Clinical trial update outlines a rollover protocol for subjects who responded in Mateon Therapeutics' Phase 2 neuroendocrine tumor study 4218s.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Snippet

Sponsor: Mateon Therapeutics | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED